Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 346.5 EUR 0.43% Market Closed
Market Cap: 2.9B EUR

Gross Margin
Virbac SA

53.8%
Current
49%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
53.8%
=
Gross Profit
953.3m
/
Revenue
1.8B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
FR
Virbac SA
PAR:VIRP
2.9B EUR
54%
US
Eli Lilly and Co
NYSE:LLY
985.4B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
506.1B USD
68%
CH
Roche Holding AG
SIX:ROG
252.5B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
210.2B GBP
82%
CH
Novartis AG
SIX:NOVN
207.2B CHF
76%
US
Merck & Co Inc
NYSE:MRK
246.7B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
82%
IE
Endo International PLC
LSE:0Y5F
209B USD
68%
US
Pfizer Inc
NYSE:PFE
142.4B USD
75%
No Stocks Found

Virbac SA
Glance View

Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.

VIRP Intrinsic Value
337.93 EUR
Overvaluation 2%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
53.8%
=
Gross Profit
953.3m
/
Revenue
1.8B
What is the Gross Margin of Virbac SA?

Based on Virbac SA's most recent financial statements, the company has Gross Margin of 53.8%.

Back to Top